Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus News 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Yet patience is essential if you want exposure to the small-cap biotech sector. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. That also means negative earnings (they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage program. They wrote silver off as a "boring metal," but its move above $33 has forced analysts to reconsider what's really driving this market. With AI hardware, EVs, solar, and next-gen electronics all dependent on silver — while global supply continues to lag — this quiet setup is starting to look like one of the most overlooked opportunities in the commodities space.
Most investors still haven't connected the dots, which is why this new silver forecast guide breaks down the fundamentals behind the move, the real pressure building beneath the surface, and the steps to consider before silver becomes front-page news. Get the Silver Forecast Now Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically attract the analyst coverage and institutional investment that can materially change their valuations. Still, getting in on a promising medical stock early can deliver outsized returns. A single successful drug can produce 3x, 5x, or even 10x gains. Many others never pan out. That's why investors who pursue penny stocks often spread capital across many biotech names — if it's a numbers game, diversification can help manage the odds. With that in mind, here are two small-cap biotech stocks with significant risk but the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's leading digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the opportunity is meaningful. The company is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer. Mainz Biomed reported positive topline results in October, though commercial approval remains years away. Risks are substantial. ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue remains limited. That concern was reflected in the company's Sept. 26 SEC filing, which included “going concern” language. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that capital helps keep the MYNZ share price above $1 and avoids a delisting notice. The company must generate materially higher revenue to change its financial profile. If it succeeds, a relatively small investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral strategy — but it carries the financial risk typical of speculative biotech stocks. The company is developing a novel class of antivirals based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces and lure viruses to bind with them, neutralizing the pathogens before they can infect real cells. If validated in human trials, this approach could represent a new method for treating infectious diseases. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance programs. Recent filings show limited cash on hand, and investors should expect potential dilution. Nevertheless, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space. Both companies illustrate the upside and downside of small-cap biotech investing: long timelines, high binary risk, and the potential for very large rewards if clinical or commercial milestones are met. Diversification and careful position sizing are prudent when allocating to these speculative names.
| 
